Drug Trial Radar · NCT05988008
A Study of CCX168 in Japanese and Caucasian Healthy Adult Males
Last checked: Nov 20, 2026Latest source record: Aug 14, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
80
Actual
Start
Oct 23, 2017
Primary completion
Jan 26, 2018
Study completion Sep 20, 2018
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Aug 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 20 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objectives of the study will be to investigate the safety and pharmacokinetics of a single oral administration and a twice-daily multiple oral administration of CCX168 in Japanese healthy adult males; and to compare the pharmacokinetics of a single oral administration and a twice-daily multiple oral administration of CCX168 between Japanese and Caucasian healthy adult males.
Conditions
- Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Interventions
CCX168Drug
Administered orally.
PlaceboDrug
Administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Experiencing Adverse EventsTime frame: Up to 14 days
- Number of Participants Experiencing Adverse Drug ReactionsTime frame: Up to 14 days
- Number of Participants Experiencing Clinically Significant Changes in Vital Sign ParametersTime frame: Up to 14 days
- Number of Participants Experiencing Clinically Significant Changes in Electrocardiogram (ECG) ParametersTime frame: Up to 14 days
- Number of Participants Experiencing Clinically Significant Changes in Clinical Laboratory ParametersTime frame: Up to 14 days
- Maximum Plasma Concentration (Cmax) of CCX168Time frame: Up to 14 days
- Cmax of CCX168-M1 (Metabolite)Time frame: Up to 14 days
- Time of Cmax (tmax) of CCX168Time frame: Up to 14 days
- Tmax of CCX168-M1Time frame: Up to 14 days
- Area Under the Plasma Concentration Time Curve (AUC) from Time 0 to Infinity (AUC0-inf) of CCX168Time frame: Up to 14 days
- AUC0-inf of CCX168-M1Time frame: Up to 14 days
- AUC from Time 0 to Time of Last Measurable Plasma Concentration (AUC0-tz) of CCX168Time frame: Up to 14 days
- AUC0-tz of CCX168-M1Time frame: Up to 14 days
- AUC During a Dosing Interval of CCX168Time frame: Cohorts B and D only: Up to Hour 12 post-dose on Days 1 - 7
- AUC During a Dosing Interval of CCX168-M1Time frame: Cohorts B and D only: Up to Hour 12 post-dose on Days 1 - 7
- Terminal Elimination Half-life of CCX168Time frame: Up to 14 days
- Terminal Elimination Half-life of CCX168-M1Time frame: Up to 14 days
- Apparent Oral Clearance of CCX168Time frame: Up to 14 days
- Apparent Volume of Distribution During the Terminal Phase of CCX168Time frame: Up to 14 days
- Mean Residence Time to Infinity of CCX168Time frame: Up to 14 days
- Accumulation Ratio of CCX168Time frame: Cohorts B and D only: Up to 14 days
- Accumulation Ratio of CCX168-M1Time frame: Cohorts B and D only: Up to 14 days
- Trough Plasma Concentration at the End of Dosing Interval of CCX168Time frame: Cohorts B and D only: Up to 14 days
- Trough Plasma Concentration at the End of Dosing Interval of CCX168-M1Time frame: Cohorts B and D only: Up to 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sumida Hospital, SOUSEIKAI Global Clinical Research Center
Sumida City, Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.